Science. Medicine. Technology. Living longer.

,

Longevica Wants to Turn a 16,000-Animal Longevity Screen Into New Drugs

Longevica says a $13 million screen tested 1,033 compounds in more than 16,000 mice. Its new advisory board may help build a pipeline, but the full screen has not been published for independent review.

Researcher reviewing survival curves from a large mouse longevity and compound-screening study

The bottom line: Longevica Therapeutics says it spent $13 million screening 1,033 compounds across more than 16,000 mice and has now assembled an advisory group to turn that private dataset into drugs, repurposing programs, AI models and pet-health products. The scale is notable. The underlying lifespan results have not been presented in a peer-reviewed paper that allows independent evaluation.

Large animal longevity studies are expensive and slow. A mouse may need to be followed for years, and every additional compound adds more animals, dosing, pathology and data. Longevica Therapeutics says it has already built an unusually large dataset. Its new scientific advisory board is meant to help convert that asset into a development pipeline.

What the company says it did

According to Longevica’s September 29 announcement, the company invested four years and $13 million in a full-lifespan screening program at The Jackson Laboratory. It says 1,033 small molecules were tested in more than 16,000 mice over their natural lifespans.

Company materials describe the library as spanning 62 pharmacological classes and including drugs, drug-like molecules, vitamins, supplements, food additives and natural compounds. Longevica says more than 60 compounds extended lifespan by over 10 percent and five produced gains of 16 to 22 percent. It has not publicly identified all of the compounds or supplied a complete study report in the announcement.

Older company pages describe 20,000 long-lived female mice, while the current corporate release uses more than 16,000 subjects. That discrepancy may reflect enrolled animals versus analyzable subjects, different phases, or a change in how the program is counted. The public materials do not explain it.

Who joined the advisory effort

The announced group spans basic biology, computation, translation, safety and finance:

  • Steven Garan, director of CRE Aging at UC Berkeley, is presented as chief scientific and technology advisor, with expertise in bioinformatics, phenomics, caloric-restriction research and machine learning.
  • Alexey Ryazanov, a Rutgers pharmacology professor and co-inventor on a Longevica patent, is credited with the original concept for the mouse screen.
  • Adrian Salic, a Harvard Medical School professor, brings cell-signaling expertise, including work on the Hedgehog pathway.
  • Mike Zack and Aishwarya Kundu add multi-omics, precision medicine, translational research and adaptive trial-design experience.
  • Jitendra Kanodia, Sanket Mishra, Nishtha Dwivedi and Amit Gupta cover quantitative pharmacology, medicinal chemistry, product safety and clinical execution.
  • Allan Gobbs and Ali Tahir advise on financing, partnerships and corporate development.

These appointments can improve how a preclinical program is designed and evaluated. They are not evidence that any candidate works.

What Longevica plans to build

The company describes four routes from the dataset. First, it wants to develop two new drug classes based on what it calls candidate mechanisms of lifespan extension. Second, it plans to repurpose screened compounds for cardiovascular, metabolic, fibrotic and systemic diseases. Third, it intends to train machine-learning models on full-lifespan outcomes to identify druggable targets. Fourth, it is exploring formulations for companion animals.

These are development strategies, not clinical results. An algorithm trained on a large private dataset may be useful, but performance depends on study quality, dosing, controls, strain, sex, husbandry and the reliability of the underlying labels. Size alone cannot correct bias in experimental design.

What is published and what is not

Longevica lists a patent family titled “Compositions and Methods for Promoting Longevity,” along with several pending patent applications. Patents establish intellectual-property claims. They do not provide the same scrutiny as a peer-reviewed methods-and-results paper.

A search of the company’s publications page and biomedical literature did not locate a peer-reviewed report presenting the full 1,033-compound screen, its protocol, complete survival curves, statistical corrections, pathology, adverse effects or replication. The company may hold substantial unpublished data, but outsiders cannot presently verify the headline efficacy numbers from the public record.

This distinction is especially important in lifespan research. Testing hundreds of compounds creates a large multiple-comparison problem. Researchers need to know how groups were randomized, whether staff were blinded, how many animals received each treatment, which doses were used, how deaths were classified, whether results survived correction for multiple testing and whether hits reproduced in an independent cohort.

What would make the program clinically meaningful

The next credible steps would include:

  • publication of the screen’s full methods and results, including negative findings;
  • independent replication of the strongest hits in genetically diverse mice of both sexes;
  • evidence that longer life did not come with worse health or hidden toxicity;
  • mechanistic studies showing a plausible target and exposure-response relationship;
  • pharmacology and safety packages suitable for an investigational new drug application;
  • human trials built around a defined disease or validated clinical endpoint, not a vague anti-aging claim.

The Lifespan Brief assessment

A full-lifespan screen of this reported scale could be a valuable discovery resource. Building a multidisciplinary advisory group is a sensible operational step toward testing that possibility.

For now, the central evidence remains a company claim supported by patents and corporate descriptions, not an independently reviewable publication. Forming an advisory board is a business and scientific-development milestone. It does not show that Longevica has a therapy that extends healthy life in people.

Primary sources

This article is for general information and is not investment or medical advice.